• Revenue of approximately $1.075 billion and net profit after tax of approximately $200 million in the first half of FY26
• Approximately 13% growth in reported operating revenue and approximately 31% growth in reported net profit after tax compared to the first half of FY25
• Outlook for the full FY26 remains unchanged, with operating revenue in the range of $2.15 billion to $2.25 billion and net profit after tax in the range of $390 million to $440 million

Fisher & Paykel Healthcare Corporation Limited has provided guidance for the first half of the 2026 financial year, which ends on 30 September 2025. At 31 July 2025 exchange rates, the guidance assumptions include a continuation of the current trading environment, resulting in revenue of approximately $1.075 billion and net profit after tax of approximately $200 million. This would equate to approximately 13% growth in reported operating revenue and approximately 31% growth in reported net profit after tax, compared to the first half of the 2025 financial year. Managing Director and CEO Lewis Gradon stated that the company had a very strong first half last year, with 17% revenue growth in constant currency, and an ongoing change in clinical practice to the company's Hospital therapies continues to contribute to the outlook for strong growth for the first half of this year. The company's outlook for the full 2026 financial year remains unchanged, with operating revenue in the range of approximately $2.15 billion to $2.25 billion and net profit after tax in the range of approximately $390 million to $440 million. This outlook now includes an estimated 75-basis point impact of US tariffs on hospital products sourced from New Zealand. The company also announced that Director Pip Greenwood will retire from the board of Fisher & Paykel Healthcare with effect from 1 September 2025.

Revenue of approximately $1.075 billion and net profit after tax of approximately $200 million in the first half of FY26. Operating revenue in the range of approximately $2.15 billion to $2.25 billion and net profit after tax in the range of approximately $390 million to $440 million for the full FY26.

The company's outlook for the full 2026 financial year remains unchanged, with operating revenue in the range of approximately $2.15 billion to $2.25 billion and net profit after tax in the range of approximately $390 million to $440 million. This outlook now includes an estimated 75-basis point impact of US tariffs on hospital products sourced from New Zealand.